Serenus Biotherapeutics Enters Agreement with Hanmi Pharmaceutical to Bring Combination Therapy to Treat Growing Problem of Hypertension in Africa

Drug will help combat epidemic of cardiovascular disease, the leading cause of death in adults over 30 in Sub-Saharan Africa

Serenus Biotherapeutics, which is bridging the divide between the world’s leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today said that it has entered into an agreement with Hanmi Pharmaceutical Co. Ltd, to supply Amosartan, Hanmi’s combination therapy for the treatment of hypertension, to patients in Africa.